United Therapeutics counsel sells 8,300 shares

Q: What insider transaction did UTHR report for EVP & General Counsel Paul Mahon?

UTHR reported that Paul A. Mahon exercised 8,300 stock options$146.038,300 common shares</b in multiple open-market transactions on the same date.

Q: How many United Therapeutics options does the insider hold after these transactions?

After exercising 8,300 options, Paul A. Mahon holds 47,540 stock options

Q: What type of securities were involved in this UTHR Form 4 filing?

The filing involves stock options8,300 common shares</b, followed by open-market sales of those common shares.

UNITED THERAPEUTICS Corp (UTHR) reported that executive vice president and general counsel Paul A. Mahon exercised employee stock options and sold the resulting shares on September 17, 2026.

Available on EDGAR 09/18/2026 - 04:41 PM EDT Accepted by SEC EDGAR 09/18/2026 - 04:40 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp (UTHR) reported that executive vice president and general counsel Paul A. Mahon exercised employee stock options and sold the resulting shares on September 17, 2026. He exercised 8,300 stock options$146.03

On the same date, he sold 8,300 shares$496–$50247,540 stock optionsRule 10b5-1 trading plan

Insider Trade Summary 10b5-1

Exercise and Sale: 8,300 shares ($2.92M approx. pre-tax spread)

Exercise and Sale 9 txns

Insider MAHON PAUL A

Role EVP & GENERAL COUNSEL

Sold 8,300 shs ($4.13M)

Approx. gross sale proceeds $4.13M

Approx. exercise cost $1.21M

Approx. pre-tax spread $2.92M

Type	Security	Shares	Price	Value
Exercise	Stock Option ^F1	8,300	$0.00	$0.00
Exercise	Common Stock ^F1	8,300	$146.03	$1.21M
Sale	Common Stock ^{F1, F2}	1,579	$495.967	$783K
Sale	Common Stock ^{F1, F3}	2,873	$496.5758	$1.43M
Sale	Common Stock ^{F1, F4}	1,400	$497.5434	$697K
Sale	Common Stock ^{F1, F5}	843	$498.737	$420K
Sale	Common Stock ^{F1, F6}	1,160	$499.7515	$580K
Sale	Common Stock ^{F1, F7}	125	$500.8018	$63K
Sale	Common Stock ^{F1, F8}	320	$501.5806	$161K

Holdings After Transaction: Stock Option — 47,540 contracts (Direct); Common Stock — 45,172 shares (Direct)

Footnotes (8)

F1. This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
F2. This transaction was executed in multiple trades at prices ranging from $495.09 to $496.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3. This transaction was executed in multiple trades at prices ranging from $496.12 to $497.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4. This transaction was executed in multiple trades at prices ranging from $497.12 to $498.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5. This transaction was executed in multiple trades at prices ranging from $498.3225 to $498.9375. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6. This transaction was executed in multiple trades at prices ranging from $499.355 to $500.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7. This transaction was executed in multiple trades at prices ranging from $500.485 to $501.095. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8. This transaction was executed in multiple trades at prices ranging from $501.53 to $501.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Options exercised: 8,300 options Exercise (strike) price: $146.03 per share Shares sold: 8,300 shares +4 more

7 metrics

Options exercised 8,300 options Stock options exercised into common stock on September 17, 2026

Exercise (strike) price $146.03 per share Exercise price of stock options converted into common stock

Shares sold 8,300 shares Total United Therapeutics common shares sold on September 17, 2026

Sale price range $495.09–$501.61 per share Price ranges across multiple trade executions disclosed in footnotes

Weighted average sale prices About $495.97–$501.58 per share Reported weighted average prices for the individual sale lots

Options held after transaction 47,540 options Stock options held directly by Paul A. Mahon following the exercise

Option term March 15, 2020 to March 15, 2027 Option exercise date and expiration date for the exercised grant

Key Terms

Rule 10b5-1 plan, stock options, weighted average price, open-market transactions, +1 more

5 terms

Rule 10b5-1 plan regulatory

"exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

stock options financial

"This is an exercise of stock options and sale of the resulting shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

weighted average price financial

"The price reported above reflects the weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market transactions financial

"Sale in open market or private transaction"

Open-market transactions are purchases or sales of a company’s securities that take place on public exchanges rather than through private agreements. They matter to investors because these trades change the number of shares available, can move the stock price, and often signal management’s view of the company’s value—like a store restocking or clearing shelves, altering supply and the price shoppers see.

exercise or conversion of derivative security financial

"Exercise or conversion of derivative security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did UTHR report for EVP & General Counsel Paul Mahon?

UTHR reported that Paul A. Mahon exercised 8,300 stock options$146.038,300 common shares

At what prices were the United Therapeutics (UTHR) shares sold in this Form 4?

The 8,300 United Therapeutics shares were sold in multiple trades at weighted average prices around $496–$502$495.09$501.61

Were the UTHR insider transactions made under a Rule 10b5-1 plan?

Yes. The filing states that the option exercise and related share sales were conducted under a pre-arranged Rule 10b5-1 trading planAugust 11, 2025.

How many United Therapeutics options does the insider hold after these transactions?

After exercising 8,300 options, Paul A. Mahon holds 47,540 stock options

What type of securities were involved in this UTHR Form 4 filing?

The filing involves stock options8,300 common shares

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAHON PAUL A

(Last)

(First)

(Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING

MARYLAND

20910

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP & GENERAL COUNSEL

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/17/2026		M⁽¹⁾		8,300	A	$146.03	53,472	D
Common Stock	09/17/2026		S⁽¹⁾		1,579	D	$495.967⁽²⁾	51,893	D
Common Stock	09/17/2026		S⁽¹⁾		2,873	D	$496.5758⁽³⁾	49,020	D
Common Stock	09/17/2026		S⁽¹⁾		1,400	D	$497.5434⁽⁴⁾	47,620	D
Common Stock	09/17/2026		S⁽¹⁾		843	D	$498.737⁽⁵⁾	46,777	D
Common Stock	09/17/2026		S⁽¹⁾		1,160	D	$499.7515⁽⁶⁾	45,617	D
Common Stock	09/17/2026		S⁽¹⁾		125	D	$500.8018⁽⁷⁾	45,492	D
Common Stock	09/17/2026		S⁽¹⁾		320	D	$501.5806⁽⁸⁾	45,172	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$146.03	09/17/2026		M⁽¹⁾			8,300	03/15/2020	03/15/2027	Common Stock	8,300	$0.00	47,540	D

Explanation of Responses:

1. This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.

2. This transaction was executed in multiple trades at prices ranging from $495.09 to $496.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $496.12 to $497.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $497.12 to $498.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $498.3225 to $498.9375. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $499.355 to $500.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $500.485 to $501.095. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $501.53 to $501.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR